Cargando…

Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study

AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahangir, Umar, Khan, Asim Ali, Kapoor, Prem, Jalees, Farhan, Urooj, Shaista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097930/
https://www.ncbi.nlm.nih.gov/pubmed/25035636
http://dx.doi.org/10.4103/0975-7406.130975
_version_ 1782326254502936576
author Jahangir, Umar
Khan, Asim Ali
Kapoor, Prem
Jalees, Farhan
Urooj, Shaista
author_facet Jahangir, Umar
Khan, Asim Ali
Kapoor, Prem
Jalees, Farhan
Urooj, Shaista
author_sort Jahangir, Umar
collection PubMed
description AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group ‘A’ thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group ‘B’ thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group ‘C’ 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. RESULTS: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well.
format Online
Article
Text
id pubmed-4097930
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-40979302014-07-17 Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study Jahangir, Umar Khan, Asim Ali Kapoor, Prem Jalees, Farhan Urooj, Shaista J Pharm Bioallied Sci Original Article AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group ‘A’ thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group ‘B’ thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group ‘C’ 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. RESULTS: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4097930/ /pubmed/25035636 http://dx.doi.org/10.4103/0975-7406.130975 Text en Copyright: © Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jahangir, Umar
Khan, Asim Ali
Kapoor, Prem
Jalees, Farhan
Urooj, Shaista
Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title_full Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title_fullStr Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title_full_unstemmed Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title_short Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
title_sort evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: a randomized, standard controlled clinical study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097930/
https://www.ncbi.nlm.nih.gov/pubmed/25035636
http://dx.doi.org/10.4103/0975-7406.130975
work_keys_str_mv AT jahangirumar evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy
AT khanasimali evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy
AT kapoorprem evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy
AT jaleesfarhan evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy
AT uroojshaista evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy